Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Drug-induced liver injury (DILI) is a major cause of acute liver failure (ALF) and one of the leading indications for liver transplantation in Western societies. Given the wide use of both prescribed and over the counter drugs, DILI has become a major health issue for which there is a pressing need to find novel and effective therapies. Although significant progress has been made in understanding the molecular mechanisms underlying DILI, our incomplete knowledge of its pathogenesis and inability to predict DILI is largely due to both discordance between human and animal DILI in preclinical drug development and a lack of models that faithfully recapitulate complex pathophysiological features of human DILI. This is exemplified by the hepatotoxicity of acetaminophen (APAP) overdose, a major cause of ALF because of its extensive worldwide use as an analgesic. Despite intensive efforts utilising current animal and in vitro models, the mechanisms involved in the hepatotoxicity of APAP are still not fully understood. In this expert Consensus Statement, which is endorsed by the European Drug-Induced Liver Injury Network, we aim to facilitate and outline clinically impactful discoveries by detailing the requirements for more realistic human-based systems to assess hepatotoxicity and guide future drug safety testing. We present novel insights and discuss major players in APAP pathophysiology, and describe emerging in vitro and in vivo pre-clinical models, as well as advanced imaging and in silico technologies, which may improve prediction of clinical outcomes of DILI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current knowledge on exosome biogenesis and release
Hessvik, N. P., & Llorente, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2595-9 · Cited by 2,362
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Vascularized and functional human liver from an iPSC-derived organ bud transplant
Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T., Zhang, R.-R., Ueno, Y., Zheng, Y.-W., Koike, N., et al. (2013) · Nature · doi:10.1038/nature12271 · Cited by 2,170 · cited 1×
“152 153 – 155 As an alternative to primary hepatocytes, iPSC-derived cultures of HLCs have several applications for early preclinical hepatotoxicity assessment and drug screening in 2D and 3D culture systems.”
Background3D bioprinting of collagen to rebuild components of the human heart
Lee, A., Hudson, A. R., Shiwarski, D. J., Tashman, J. W., Hinton, T. J., Yerneni, S., Bliley, J. M., Campbell, P. G., & Feinberg, A. W. (2019) · Science · doi:10.1126/science.aav9051 · Cited by 1,782 · cited 1×
“167 Many novel integrative bioengineering approaches have been adopted, with new designs and innovations continuing to evolve at a rapid pace.”
BackgroundInduced pluripotent stem cell technology: a decade of progress.
Shi, Y., Inoue, H., Wu, J. C., & Yamanaka, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.245 · Cited by 1,525 · cited 1×
“129,130 134 Early protocols for HLC generationwere based on addition of stage-speci fi c morphogenic cues mimicking hepatic embryonic development.”
Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation
Kalra, H., Simpson, R. J., Ji, H., Aikawa, E., Altevogt, P., Askenase, P., Bond, V. C., Borràs, F. E., Breakefield, X., Budnik, V., et al. (2012) · PLoS Biology · doi:10.1371/journal.pbio.1001450 · Cited by 1,367 · cited 1×
“81 In the liver, the fi rst descriptions of hepatocyte-derived vesicles were obtained from primary culture of rat hepatocytes, 82 and isolated hepatic stem cell cultures.”
BackgroundHighly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells
Si-Tayeb, K., Noto, F. K., Nagaoka, M., Li, J., Battle, M. A., Duris, C., North, P. E., Dalton, S., & Duncan, S. A. (2010) · Hepatology · doi:10.1002/hep.23354 · Cited by 1,282
Richardson, D. S., & Lichtman, J. W. (2015) · Cell · doi:10.1016/j.cell.2015.06.067 · Cited by 1,095
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Liver sinusoidal endothelial cells: Physiology and role in liver diseases
Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., & Rautou, P.-E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.009 · Cited by 1,047
Cellular senescence drives age-dependent hepatic steatosis
Ogrodnik, M., Miwa, S., Tchkonia, T., Tiniakos, D., Wilson, C. L., Lahat, A., Day, C. P., Burt, A., Palmer, A., Anstee, Q. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15691 · Cited by 1,044
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Self-citationBjörnsson, E. S., Bergmann, O. M., Björnsson, H. K., Kvaran, R. B., & Olafsson, S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.006 · Cited by 865
Maschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., Hübner, J., Lindner, M., Drewell, C., Bauer, S., Thomas, A., et al. (2015) · Lab on a Chip · doi:10.1039/c5lc00392j · Cited by 861
Robust expansion of human hepatocytes in Fah−/−/Rag2−/−/Il2rg−/− mice
Azuma, H., Paulk, N., Ranade, A., Dorrell, C., Al-Dhalimy, M., Ellis, E., Strom, S., Kay, M. A., Finegold, M., & Grompe, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1326 · Cited by 835
Wilkening, S., Stahl, F., & Bader, A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.8.1035 · Cited by 794 · cited 1×
“For instance, the human hepatoma cell lines HuH7 and HepG2 do not have the full repertoire of XMEs, 255,256 whereas rodent hepatocytes do not have the same pro fi le of drug metabolism as human hepatocytes, as discussed in the section ‘ Towards capturing hepatocellular complexity ’ .”
BackgroundBell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
Chang, L., Kamata, H., Solinas, G., Luo, J.-L., Maeda, S., Venuprasad, K., Liu, Y.-C., & Karin, M. (2006) · Cell · doi:10.1016/j.cell.2006.01.021 · Cited by 706 · cited 1×
“No differences in APAP hepatotoxicity in Jnk1 knockout mice were observed, 26 despite a clear pro-apoptotic and pro-fi brogenic function of Jnk1 in tumour necrosis factor (TNF)-induced cell death, 29 and in liver fi brosis.”
BackgroundMulti-tissue interactions in an integrated three-tissue organ-on-a-chip platform
Skardal, A., Murphy, S. V., Devarasetty, M., Mead, I., Kang, H.-W., Seol, Y.-J., Shrike Zhang, Y., Shin, S.-R., Zhao, L., Aleman, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08879-x · Cited by 623 · cited 1×
“183 Increasing OoC complexity has recently been explored with up to 10 interconnected organs to explore drug and metabolite bio-distribution together with a pharmacokinetic model.”
BackgroundA liver-on-a-chip platform with bioprinted hepatic spheroids
Bhise, N. S., Manoharan, V., Massa, S., Tamayol, A., Ghaderi, M., Miscuglio, M., Lang, Q., Shrike Zhang, Y., Shin, S. R., Calzone, G., et al. (2016) · Biofabrication · doi:10.1088/1758-5090/8/1/014101 · Cited by 615
Hanawa, N., Shinohara, M., Saberi, B., Gaarde, W. A., Han, D., & Kaplowitz, N. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708916200 · Cited by 527
Reproducing human and cross-species drug toxicities using a liver-chip
Jang, K.-J., Otieno, M. A., Ronxhi, J., Lim, H.-K., Ewart, L., Kodella, K. R., Petropolis, D. B., Kulkarni, G., Rubins, J. E., Conegliano, D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax5516 · Cited by 511 · cited 1×
“170 Crucially, this system could identify both species-speci fi c toxicity of drugs, such as APAP, and identify toxic events in hepatocyte and vascular channels.”
BackgroundInterconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies
Edington, C. D., Chen, W. L. K., Geishecker, E., Kassis, T., Soenksen, L. R., Bhushan, B. M., Freake, D., Kirschner, J., Maass, C., Tsamandouras, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22749-0 · Cited by 487 · cited 1×
“184 At present, OoC technology is still in its infancy, and while it is demonstrating important tissue engineering principles and proof of concept, complexity and interactions resulting from multi-organ models are presently very challenging to decipher, whilst being inherently incompatible with HTS.”
BackgroundWagner, I., Materne, E.-M., Brincker, S., Süßbier, U., Frädrich, C., Busek, M., Sonntag, F., Sakharov, D. A., Trushkin, E. V., Tonevitsky, A. G., et al. (2013) · Lab on a Chip · doi:10.1039/c3lc50234a · Cited by 476 · cited 1×
“180 More complex multi-organ models are under development, including: i) Liver/cardiac/muscle/ neuronal system to investigate drug toxicity (doxorubicin, atorvastatin, valproic acid, APAP and N-acetyl-m-aminophenol), 181 and ii) a gut/skin/ liver/kidney system in which organ-level functions were…”
MethodC-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity
Gunawan, B. K., Liu, Z., Han, D., Hanawa, N., Gaarde, W. A., & Kaplowitz, N. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.045 · Cited by 471
Generation of Functional Human Hepatic Endoderm From Human Induced Pluripotent Stem Cells
Sullivan, G. J., Hay, D. C., Park, I.-H., Fletcher, J., Hannoun, Z., Payne, C. M., Dalgetty, D., Black, J. R., Ross, J. A., Samuel, K., et al. (2010) · Hepatology · doi:10.1002/hep.23335 · Cited by 445
Self-citationMulti-Organ toxicity demonstration in a functional human in vitro system composed of four organs
Oleaga, C., Bernabini, C., Smith, A. S. T., Srinivasan, B., Jackson, M., McLamb, W., Platt, V., Bridges, R., Cai, Y., Santhanam, N., et al. (2016) · Scientific Reports · doi:10.1038/srep20030 · Cited by 442 · cited 1×
“…models are under development, including: i) Liver/cardiac/muscle/ neuronal system to investigate drug toxicity (doxorubicin, atorvastatin, valproic acid, APAP and N-acetyl-m-aminophenol), 181 and ii) a gut/skin/ liver/kidney system in which organ-level functions were maintained for 28 days.”
MethodDifferentiation of human embryonic stem cells into hepatocytes in 2D and 3D culture systems in vitro
Baharvand, H., Hashemi, S. M., Kazemi Ashtiani, S., & Farrokhi, A. (2006) · The International Journal of Developmental Biology · doi:10.1387/ijdb.052072hb · Cited by 429
Adverse outcome pathways: opportunities, limitations and open questions
Leist, M., Ghallab, A., Graepel, R., Marchan, R., Hassan, R., Bennekou, S. H., Limonciel, A., Vinken, M., Schildknecht, S., Waldmann, T., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2045-3 · Cited by 394
Preclinical models of non-alcoholic fatty liver disease
Santhekadur, P. K., Kumar, D. P., & Sanyal, A. J. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.10.031 · Cited by 380
Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH
Caballero, F., Fernández, A., De Lacy, A. M., Fernández-Checa, J. C., Caballería, J., & García-Ruiz, C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.016 · Cited by 368 · cited 4×
“Abbreviations ADME, absorption, distribution, metabolism, excretion; AIF, apoptosis inducing factor; ALF, acute liver failure; AOP, adverse outcome pathways; ASK1, apoptosis signal-regulating kinase-1; ATF6, activating transcription factor 6; CYP, cytochrome P450; DILI, drug-induced liver injury; ECM, extracellular ma…”
BackgroundInfluentialSelf-citationMossanen, J. C., Krenkel, O., Ergen, C., Govaere, O., Liepelt, A., Puengel, T., Heymann, F., Kalthoff, S., Lefebvre, E., Eulberg, D., et al. (2016) · Hepatology · doi:10.1002/hep.28682 · Cited by 325 · cited 1×
“33”
Mechanisms of drug-induced liver injury
Yuan, L., & Kaplowitz, N. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.07.002 · Cited by 322
Karch, J., Kwong, J. Q., Burr, A. R., Sargent, M. A., Elrod, J. W., Peixoto, P. M., Martinez-Caballero, S., Osinska, H., Cheng, E. H.-Y., Robbins, J., et al. (2013) · eLife · doi:10.7554/elife.00772 · Cited by 290 · cited 1×
“…outer membrane and allowing the exit of molecules less than 1,500 Da, including cytochrome c, apoptosis inducing factor (AIF) and endonuclease G. 46 Although release of cytochrome c and AIF is a hallmark of apoptosis, as they activate caspase 3/7 and lead to nuclear DNA cleavage, respectively,…”
BackgroundIdentification of small molecules for human hepatocyte expansion and iPS differentiation
Shan, J., Schwartz, R. E., Ross, N. T., Logan, D. J., Thomas, D., Duncan, S. A., North, T. E., Goessling, W., Carpenter, A. E., & Bhatia, S. N. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1270 · Cited by 254
Human hepatic organoids for the analysis of human genetic diseases
Guan, Y., Xu, D., Garfin, P. M., Ehmer, U., Hurwitz, M., Enns, G., Michie, S., Wu, M., Zheng, M., Nishimura, T., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.94954 · Cited by 243 · cited 1×
“152 153 – 155 As an alternative to primary hepatocytes, iPSC-derived cultures of HLCs have several applications for early preclinical hepatotoxicity assessment and drug screening in 2D and 3D culture systems.”
BackgroundColl, M., Perea, L., Boon, R., Leite, S. B., Vallverdú, J., Mannaerts, I., Smout, A., El Taghdouini, A., Blaya, D., Rodrigo-Torres, D., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.027 · Cited by 233 · cited 1×
“In this regard, Coll and collaborators 151 generated HSC-like cells displaying features of quiescent HSCs that could be activated by in fl ammatory and pro-fi brogenic stimuli, such as lipopolysaccharide or TGF-b .”
BackgroundSelf-citationLong‐term maintenance of a microfluidic 3D human liver sinusoid
Prodanov, L., Jindal, R., Bale, S. S., Hegde, M., McCarty, W. J., Golberg, I., Bhushan, A., Yarmush, M. L., & Usta, O. B. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.25700 · Cited by 214 · cited 1×
“171 This has also been demonstrated using hepatocytes co-cultured with stromal cells present in vivo ( e.g. 174 Whilst an organotypic human liver C3A cell line/HUVEC co-culture system demonstrated profound susceptibility to APAP-induced toxicity in endothelial cells (re fl ecting the situation found…”
MethodSmall-Molecule-Driven Hepatocyte Differentiation of Human Pluripotent Stem Cells
Siller, R., Greenhough, S., Naumovska, E., & Sullivan, G. J. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.04.001 · Cited by 203
Self-citationBell, C. C., Lauschke, V. M., Vorrink, S. U., Palmgren, H., Duffin, R., Andersson, T. B., & Ingelman-Sundberg, M. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074369 · Cited by 201 · cited 1×
“Human iPSC-derived HLCs have similarattributes to the hepatoma cell lineHepG2 139 and HepaRG cells (at least in 3D culture), 140 with lower metabolic activity compared with PHHs, and exhibit a mixed adult/foetal phenotype.”
MethodWin, S., Than, T. A., Han, D., Petrovic, L. M., & Kaplowitz, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.276089 · Cited by 197 · cited 1×
“Activated JNK (p-JNK) trans-locates to mitochondria and binds to the Sab (SH3BP5) protein on the outer mitochondrial membrane, 43,44 impairing mitochondrial respiration and enhancing the release of ROS.”
BackgroundA critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Self-citationMicroengineered Liver Tissues for Drug Testing
Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R. (2015) · SLAS Technology · doi:10.1177/2211068214566939 · Cited by 116 · cited 1×
“171 This has also been demonstrated using hepatocytes co-cultured with stromal cells present in vivo ( e.g. 174 Whilst an organotypic human liver C3A cell line/HUVEC co-culture system demonstrated profound susceptibility to APAP-induced toxicity in endothelial cells (re fl ecting the situation found…”
MethodModeling human nonalcoholic fatty liver disease (NAFLD) with an organoids-on-a-chip system
Wang, Y., Wang, H., Deng, P., Tao, T., Liu, H., Wu, S., Chen, W., & Qin, J. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00682 · Cited by 109
Avior, Y., Levy, G., Zimerman, M., Kitsberg, D., Schwartz, R., Sadeh, R., Moussaieff, A., Cohen, M., Itskovitz‐Eldor, J., & Nahmias, Y. (2015) · Hepatology · doi:10.1002/hep.27803 · Cited by 88 · cited 1×
“145 A feature of pluripotent stem cells is their ability to recapitulate aspects of liver organogenesis/ development in the dish.”
BackgroundZhou, Y., Shen, J. X., & Lauschke, V. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01093 · Cited by 85 · cited 1×
“122 122 – 124 Coupling organotypic human HepaRG cells with various combinations of NPC types: hepatic stellate cells (HSCs), KCs, and LSECs provides a rational approach to providing context-speci fi c models to investigate DILI, viz : i) Immunomodulatory (Hep-aRG:KCs), ii) vascular (HepaRG:LSECs);…”
BackgroundDeharde, D., Schneider, C., Hiller, T., Fischer, N., Kegel, V., Lübberstedt, M., Freyer, N., Hengstler, J. G., Andersson, T. B., Seehofer, D., et al. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1758-z · Cited by 58
Mechanisms of idiosyncratic drug-induced liver injury
Uetrecht, J. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2018.12.001 · Cited by 49 · cited 1×
“16 The complex and multifactorial nature of APAP hepatotoxicity extends to DILI itself.”
Background
Cited by
Drug induced liver injury – a 2023 update
Allison, R., Guraka, A., Shawa, I. T., Tripathi, G., Moritz, W., & Kermanizadeh, A. (2023) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2023.2261848 · Cited by 167
“Indeed, hepatocyte proliferation is severely inhibited in chronic liver diseases, including MASLD, alcoholic liver disease, and chronic exposure to hepatotoxins (Fernandez-Checa et al. 2021; Michalopoulos 2013; Sancho-Bru et al. 2012).”
BackgroundMicrofluidic Liver-on-a-Chip for Preclinical Drug Discovery
Fu, J., Qiu, H., & Tan, C. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041300 · Cited by 42
Biomimetic hepatic lobules from three-dimensional imprinted cell sheets
Wang, J., Huang, D., Chen, H., & Zhao, Y. (2024) · Science Bulletin · doi:10.1016/j.scib.2024.02.030 · Cited by 37
Guo, K., & van den Beucken, T. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01317-2 · Cited by 28
Development of an AI model for DILI-level prediction using liver organoid brightfield images
Tan, S., Ding, Y., Wang, W., Rao, J., Cheng, F., Zhang, Q., Xu, T., Hu, T., Hu, Q., Ye, Z., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08205-6 · Cited by 26
“By providing an early-stage, in vitro platform for hepatotoxicity evaluation, our model might signi fi cantly reduce reliance on animal models, which often struggle to predict DILI, particularly idiosyncratic DILI 28 .”
Metadata
- Authors
- Fernandez-Checa, J. C., Bagnaninchi, P., Ye, H., Sancho-Bru, P., Falcon-Perez, J. M., Royo, F., Garcia-Ruiz, C., Konu, O., Miranda, J., Lunov, O., Dejneka, A., Elfick, A., McDonald, A., Sullivan, G. J., Aithal, G. P., Lucena, M. I., Andrade, R. J., Fromenty, B., Kranendonk, M., Cubero, F. J., & Nelson, L. J.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-10
- Volume
- 75
- Issue
- 4
- Pages
- 935-959
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3173906377
- Cited by
- 126
- References
- 48
- FWCI
- 16.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.